Co-Diagnostics is advancing an Ebola assay for its Co-Dx PCR platform designed for decentralized testing, responding to the ongoing Ebola outbreak in the Democratic Republic of the Congo. This development aligns with increased global funding, including $267 million from the U.S. government for Ebola response. The company also promotes its molecular test for tuberculosis, a major health issue in Africa, at WHX Labs Johannesburg. Co-Diagnostics seeks grants to support these efforts and aims to expand rapid, accessible diagnostics in affected regions.
Co-Diagnostics' development of an Ebola assay is notable alongside Pluang's health sector activity, where 68 of 100 priced US health stocks rose today. For readers following health stocks, here is Pluang's market snapshot as of Oct 06, 2026 18:43 WIB: Aurora Cannabis Inc (ACB) rose 2.91% to USD 4.59 with a typical hold time of 25 days and 73% buy order activity; Amphastar Pharmaceuticals Inc (AMPH) fell 2.84% to USD 24.65 with a typical hold time of 16 days; and 10X Genomics Inc (TXG) rose 2.72% to USD 100.40 with a typical hold time of 93 days and 73% buy order activity.
Morgan Stanley analyst Bob Huang lowered American International Group's (AIG) price target to $80 from $81, with the stock trading around $76, indicating potential upside. AIG is set to report its Q3 2026 earnings on November 3, with investors focuse...
Vertiv Holdings, a maker of power and cooling equipment for data centers, faces mixed analyst opinions with GLJ Research rating it a "Sell" and BMO Capital giving an "Outperform" rating. Despite a recent stock pullback, the company reported a 241% in...
Apogee Enterprises reported strong fiscal Q2 results with adjusted earnings of $1.17 per share, nearly double the estimated $0.59, and revenue of $391.14 million, surpassing expectations of $362.6 million. This marks a continued trend of beating esti...
McKesson received a bullish price target of $977 from Morgan Stanley, suggesting a 6.7% upside from its current price of $915.45. The company agreed to acquire Option Care Health for $32.05 per share, valuing the deal at approximately $5.8 billion in...
Ameriprise Financial has authorized an additional $5.5 billion for share repurchases through September 2028, supported by $2.1 billion in excess capital and $2.8 billion in liquidity. The company returned $1.9 billion to shareholders in H1 2026, incl...
